转移性结直肠癌类器官的应用与展望
Applications and perspectives of metastatic colorectal cancer organoids
崔经纬 1王梦杰 1秦富豪 1王璐 2樊志敏2
作者信息
- 1. 南京中医药大学附属南京中医院肛肠科(南京 210022)
- 2. 江苏省中医肛肠疾病临床医学创新中心(南京 210022);南京中医肛肠疾病临床医学研究中心(南京 210022)
- 折叠
摘要
结直肠癌(colorectal cancer,CRC)是当前最常见的恶性肿瘤之一,具有较高的发病率和死亡率.50%以上的患者最终会出现肿瘤转移,且转移性结直肠癌(metastatic colorectal cancer,mCRC)患者对大部分药物敏感性不高,导致患者预后较差.虽然利用细胞系和患者源性异种移植模型进行mCRC的研究已较为成熟,但两者仍有较大的局限性.而患者来源肿瘤类器官作为患者衍生的三维培养物,具有模拟肿瘤体内特征、保留肿瘤细胞异质性、培养周期短及易于保存等优势,在mCRC的基础研究、药物作用机制的阐释、新药开发和个体化治疗等方面均展示出了极大的应用价值.本文概述了近年类器官技术在mCRC领域中的研究和挑战,旨在阐明类器官在mCRC中的研究价值,为后续研究提供方向.
Abstract
Currently,colorectal cancer(CRC)is one of the most malignancies in the world,with high rates of morbidity and mortality.More than 50%of patients will eventually develop tumor metastasis,and patients with metastatic colorectal cancer(mCRC)are not sensitive to most drugs,leading to a poorer prognosis for patients.Although studies of mCRC using patient-derived cancer cells and patient-derived xenografts(PDX)are mature,both still have limitations.However,patient-derived organoids(PDO)has the benefits of duplicating the immune circumstance of real tumor in vivo,preserving tumor heterogeneity,short culture cycles and easy preservation.And it has shown great application value in the fundamental study of mCRC,explanation of the mechanism of drug action,development of new drugs and individualized treatment.In order to explain the importance of organoids in mCRC research and offer directions for future research,this paper summarizes the recent studies and difficulties of organoid technology in recent years.
关键词
转移性结直肠癌/类器官/结直肠癌/结直肠肿瘤类器官/患者源性异种移植/患者肿瘤类器官Key words
Metastatic colorectal cancer/Organoids/Colorectal cancer/Colorectal cancer organoids/Patient-derived xenografts/Patients-derived organoids引用本文复制引用
基金项目
江苏省重点研发计划社会发展项目(BE2021611)
出版年
2024
国家科技期刊平台
NSTL
万方数据